Evidence map›Paper›PMID 33129099›Full record

Trial reportInternational immunopharmacology2020

Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients.

Hamed Valizadeh, Samaneh Abdolmohammadi-Vahid, Svetlana Danshina, Mehmet Ziya Gencer, Ali Ammari, Armin Sadeghi, Leila Roshangar, Saeed Aslani, Abdolreza Esmaeilzadeh, Mahnaz Ghaebi and 2 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International immunopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 5 pooled it
15.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 5 syntheses or guidelines pooled it, 269 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Article
  14. Therapeutic Potential of Plant Phenolic Acids Combating Cancer Drug Resistance.Recent advances in food, nutrition & agriculture · 2026
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Hamed ValizadehTuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran; Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Samaneh Abdolmohammadi-VahidStudent's Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Svetlana DanshinaDepartment of propaedeutics of dental diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Mehmet Ziya GencerDepartment of Family Medicine, Yassawi International Kazakh-Turkish University Hospital, Turkistan, Kazakhstan.
Ali AmmariDepartment of Surgery, Mousavi Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Armin SadeghiTuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran; Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Leila RoshangarStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Saeed AslaniDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Abdolreza EsmaeilzadehCancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Sciences, Zanjan, Iran.
Mahnaz GhaebiCancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Sciences, Zanjan, Iran.
Sepehr ValizadehDepartment of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Majid AhmadiStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: ahmadi.m@tbzmed.ac.ir.
Tabriz University of Medical Sciences · IRZanjan University of Medical Sciences · IRAhmet Yesevi University · KZSechenov University · RUTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs an ongoing worldwide health issue, Coronavirus disease 2019 (COVID-19) has been causing serious complications, including pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. However, there is no decisive treatment approach available for this disorder, which is primarily attributed to the large amount of inflammatory cytokine production. We aimed to identify the effects of Nano-curcumin on the modulation of inflammatory cytokines in COVID-19 patients.

methodForty COVID-19 patients and 40 healthy controls were recruited and evaluated for inflammatory cytokine expression and secretion. Subsequently, COVID-19 patients were divided into two groups: 20 patients receiving Nano-curcumin and 20 patients as the placebo group. The mRNA expression and cytokine secretion levels of IL-1β, IL-6, TNF-α and IL-18 were assessed by Real-time PCR and ELISA, respectively.

resultOur primary results indicated that the mRNA expression and cytokine secretion of IL-1β, IL-6, TNF-α, and IL-18 were increased significantly in COVID-19 patients compared with healthy control group. After treatment with Nano-curcumin, a significant decrease in IL-6 expression and secretion in serum and in supernatant (P = 0.0003, 0.0038, and 0.0001, respectively) and IL-1β gene expression and secretion level in serum and supernatant (P = 0.0017, 0.0082, and 0.0041, respectively) was observed. However, IL-18 mRNA expression and TNF-α concentration were not influenced by Nano-curcumin.

conclusionNano-curcumin, as an anti-inflammatory herbal based agent, may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mRNA expression and cytokine secretion in COVID-19 patients, which may cause an improvement in clinical manifestation and overall recovery.

Indexed as

COVID-19 Drug TreatmentSARS-CoV-2AdultAgedCOVID-19CurcuminCytokinesDouble-Blind MethodFemaleHumansMaleMicellesMiddle AgedNanotechnologyRNA, MessengerYoung AdultCurcuminCytokinesMicellesRNA, MessengerCOVID-19Cytokine stormIL-1βIL-6Nano-curcumin

Identifiers

PMID33129099
PMCPMC7574843
OpenAlexW3093587072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.